PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
  • Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“

REHOVOT, Israel and HEIDELBERG, Germany, February 20, 2024. AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.

AION Labs’ next startup will focus on the development of an AI/ML computational platform to identify functional regions in RNA that can be targeted with small molecules. RNA has traditionally been deemed unsuitable for small molecule binding. However, recent developments have shown that RNA levels can be modulated using small molecules, which has resulted in several candidate drugs currently in clinical trials.

RNA targeting is an emerging field and small molecule discovery of RNA modulators remains a significant challenge. It is however an area of huge potential where computational approaches are starting to deliver impact. The platform being developed will include the ranking of the most druggable regions along any given coding or non-coding RNA sequence, a prediction of the functional and off-tar…

Read More...
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules

Articles